Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
47 hedge funds and large institutions have $13.4M invested in Aptose Biosciences, Inc. in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 9 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
4% less funds holding
Funds holding: 49 → 47 (-2)
9% less capital invested
Capital invested by funds: $14.7M → $13.4M (-$1.28M)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$102K |
| 2 |
TI
Telemetry Investments
New York
|
+$59.6K |
| 3 |
Millennium Management
New York
|
+$56.9K |
| 4 |
AC
Annandale Capital
Dallas,
Texas
|
+$53.7K |
| 5 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$53.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$499K |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$377K |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$336K |
| 4 |
Morgan Stanley
New York
|
-$45.9K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Dimensional Fund Advisors
Austin,
Texas
| – | -$41K | -152 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$20K | -73 | Closed |
|
|
BFEC
53
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$12K | -44 | Closed |
|
54
Jane Street
New York
| – | -$11K | -41 | Closed |
|
|
TSS
55
Two Sigma Securities
New York
| – | -$11K | -41 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$5K | -20 | Closed |
|
57
Simplex Trading
Chicago,
Illinois
| – | -$2.69K | -10 | Closed |
|
|
AIP
58
Almanack Investment Partners
Wayne,
Pennsylvania
| – | -$2K | -7 | Closed |
|
APTO Hedge Fund Activity: Q4 2022 in Review
47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2022, worth a combined $13.4M — down 8.7% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of APTO and 7 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 11 added.
The largest buyer was Sigma Planning Corp, adding an estimated $102K. The largest seller was Nantahala Capital Management, cutting an estimated $499K.
- 47 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $13.4M of Aptose Biosciences, Inc. stock for Q4 2022, down 8.7% quarter-over-quarter.
- 7 funds opened new Aptose Biosciences, Inc. positions in Q4 2022 and 9 closed out, a net change of -2 holders.
- The largest Aptose Biosciences, Inc. buyer in Q4 2022 was Sigma Planning Corp, an estimated $102K added.
- The largest Aptose Biosciences, Inc. seller in Q4 2022 was Nantahala Capital Management, an estimated $499K sold.
Based on aggregated 13F filings for Q4 2022.